The estimated Net Worth of Amy Abernethy is at least $758 Thousand dollars as of 22 January 2019. Amy Abernethy owns over 5,000 units of Caredx Inc stock worth over $451,830 and over the last 8 years Amy sold CDNA stock worth over $306,530.
Amy has made over 4 trades of the Caredx Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Amy exercised 5,000 units of CDNA stock worth $64,400 on 22 January 2019.
The largest trade Amy's ever made was exercising 5,000 units of Caredx Inc stock on 22 January 2019 worth over $64,400. On average, Amy trades about 833 units every 97 days since 2016. As of 22 January 2019 Amy still owns at least 15,837 units of Caredx Inc stock.
You can see the complete history of Amy Abernethy stock trades at the bottom of the page.
Amy's mailing address filed with the SEC is C/O CAREDX, INC., 3260 BAYSHORE BOULEVARD, BRISBANE, CA, 94005.
Over the last 10 years, insiders at Caredx Inc have traded over $60,271,359 worth of Caredx Inc stock and bought 1,726,634 units worth $9,072,700 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Neil Gagnon, and Peter Maag. On average, Caredx Inc executives and independent directors trade stock every 17 days with the average trade being worth of $615,506. The most recent stock trade was executed by Alexander L Johnson on 20 August 2024, trading 61,023 units of CDNA stock currently worth $1,432,820.
caredx: transforming transplant patient care through novel surveillance management solutions caredx, inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. by combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, caredx is at the forefront of organ transplant surveillance and pre-transplant hla typing solutions. nasdaq:cdna about allosure® allosure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. allosure is a clinical-grade, proprietary next-generation sequencing (ngs) based test to detect donor-derived cell-free dna (dd-cfdna) in order to identify organ injury in kidney transplant recipients. allosure is analytically validated as a sensitive, specific, and precise measurement of dd-cfdna. allos
Caredx Inc executives and other stock owners filed with the SEC include: